ISPOR Asia Consortium Executive Committee

The ISPOR Asia Consortium Executive Committee consists of:

• At least one Consortium member from each country in Asia and, but not more than three members from any one country (exclusive of chapter representation). The member must reside in the country and be an ISPOR member.
• A representative from each ISPOR country/province Chapter in Asia
• Program Chairs of upcoming ISPOR Asia Pacific Conferences
• ISPOR Asia Consortium Advisory Committee Chair.

The Executive Committee initiates and facilitates ISPOR activities in the region and advises the ISPOR Board of Directors on scientific and health policy issues important in the region.

ISPOR Asia Consortium Executive Committee Membership

• Term of office for Executive Committee members is 3 year and is renewable.
• Members who are inactive (i.e. do not participate in Consortium activities via email or teleconference over a 6 month period) will be asked to resign.
• New Executive Committee members are recommended by a member of the Executive Committee and approved by the Executive Committee.

Executive Committee Officers  

The ISPOR Asia Consortium Executive Committee is led by the Chair or Chair-elect. The Chair (initially) and Chair-elect of the Executive Committee are selected by the Executive Committee members. The term of office for the Chair and Chair-elect is two years. The term for the Executive Committee members is 3 years. New Executive Committee members are recommended by a member of the Executive Committee and approved by the Executive Committee. 

• Conduct and preside over all meeting of ISPOR Asia Consortium Executive Committee
• Select a scribe for each meeting of the Consortium. The scribe prepares a summary of the meeting discussions including actions to be taken.
• Represent ISPOR Asia Consortium when called upon to do so.
• Provide a report of activities to the ISPOR Board of Directors annually.

The office of the Chair is open to any member of the Consortium Executive Committee. 

• Succeed to the office of the Chair upon completion of a 2-year term of Chair-elect.
• Conduct and preside over all meetings of ISPOR Asia Consortium Executive Committee in the absence of the Chair.
• Assist the Chair with the responsibilities of ISPOR Asia Consortium.

The office is open to any member of the Consortium Executive Committee. 

Election of the Executive and Advisory Committee Chair-elect

The Chair-elect of the Executive Committee and the Advisory Committee are an elected position. All interested Executive Committee or Advisory Committee members, respectively, are eligible to be candidates. All Executive Committee and Advisory Committee members, respectively, are eligible to vote. The candidate with the majority votes is the new Chair-elect.  The Chair conducts the election.

2008-2010 Chair:

Shanlian Hu MD, MSc, Professor, Training Center for Health Management, School of Public Health, Fudan University, Shanghai, China
E-mail: slhu@shmu.edu.cn

2008-2010 Chair-elect and 2010-2012 Chair:

Bong-Min Yang PhD, ISPOR 3rd Asia-Pacific Conference Chair, and Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea
E-mail: bmyang@snu.ac.kr

Members:

China

• Wen Chen, PhD, Chair, ISPOR 2nd Asia-Pacific Conference, Professor and Associate Dean, School of Public Health, Fudan University, Shanghai, China
• Shanlian Hu, MD. MPH, Co-chair, ISPOR 2nd Asia-Pacific Conference, Professor, Training Center for Health Management, School of Public Health, Fu Dan University, Shanghai, China
• Gordon Liu, PhD, Professor, Guanghua School of Management, Peking University, Beijing, China 

Hong Kong

• Kenneth KC Lee,  JP, BSc(Pharm), MPhil, PhD, Professor & Associate Director (External Affairs), School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China

Taiwan

• Tony Yen-Huei Tarn, MS, PhD, Senior Researcher, Health Technology Assessment Task Force, Center for Drug Evaluation, Taipei, Taiwan
• Ming-Chin Yang DrPH, Associate Professor, School of Public Health, National Taiwan University, Taipei, Taiwan Hsiao-Yi Lin, MD, FACR, Rheumatologist, Department of Medicine, Division of Immunology and Rheumatology, Veteran General Hospital-Taipei, National Yang-Ming University, Taipei, Taiwan
• Hsiao-Yi Lin MD, FACR, Chief, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, Taiwan, and (adjunct position) Associate Professor, National Yang-Ming University, Taipei, Taiwan

India

• Urmila Mukund Thatte, PhD, DNB, MD, MBBS, Professor and Head, Department of Clinical Pharmacology, Topiwala National Medical College and BYL Nair Charitable Hospital Mumbai Central, Mumba, India 
• Jawahar S. Bapna PhD, MD, MB, Professor, Pharmaceutical Management, Indian Institute of Health Management Research, Jaipur, India

Indonesia

• Ahmad Fuad Afdhal Phd, Chief Executive Officer, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia

Japan

• Isao Kamae, MD, DrPH, Chair, ISPOR 1st Asia-Pacific Conference, Professor & Chair, Graduate School of Health Management, Keio University, Kanagawa, Japan
• Shunya Ikeda MD, MS, DMSc, Assistant Professor, Department of Health Policy and Management, School of Medicine, Keio University, Japan
• Takashi Fukuda, PhD, Associate Professor, Department of Pharmacoeconomics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan
• Hiroyuki Sakamaki, MBA, Professor, Department of Clinical Economics, Faculty of Pharmaceutical Science, Meijo University, Nagoya, Japan

Malaysia

• Dr Syed Mohamed Aljunid, PhD, MD, MSc, FAMM, Professor of Health Economics and Head of Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia

Mongolia

• Ganbat Byambaa MD, MPH, MHSM (Curtin), PhD, Associate Professor and Dean for Graduate training, Scientific Secretary of Academic Council, Health Sciences University of Mongolia, Ulaanbaatar, Mongolia

Pakistan

• Anwarul Hassan Gilani MCs, PhD, S.I, National Professor of Pharmacology, Director, Drug Discovery and Natural Products Research, and Vice Chair, Research and Graduate Studies, Department of Biological and Biomedical Sciences, Aga Khan University Medical College, Karachi-74800, Pakistan
• Aamir Hameed, MBBS, FCPS, (Internal Medicine), FCPS (Cardiology), Assistant Professor and Consultant Cardiologist, Cardiology Section, Department of Medicine, The Aga Khan University, Karachi, Pakistan
• Muhammad Ashraf Janjua MA, Dean, College of Business Management, and Chief Editor, Pakistan Business Review, Karachi, Pakistan

Philippines:

• Madeleine R. Valera MD, MScCHHM, CESO IV, Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, Pasig City, Philippines

 South Korea 

• Bong-Min Yang, PhD, Chair, ISPOR 3rd Asia-Pacific Conference, and Professor of Economics, School of Public Health, Seoul National University, Seoul, Korea
• Eui-Kyung Lee PhD, Professor, Graduate School of Clinical Pharmacy, Sookmyung Women’s University, Seoul, South Korea
• Eun-Young Bae PhD, Assistant Professor, College of Health Sciences, Sanji University, Wonju, South Korea
• Sang-Cheol Bae, MD, PhD, MPH, Professor and Director, The Hospital for Rheumatic Diseases, and Head, Section for  Clinical Epidemiology and Economics, Hanyang University, Seoul, South Korea

Singapore

• Shu-Chuen Li, PhD, MS, MBA, Professor, Chair & Head, Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle, Callaghan, Australia; And Visiting Professor, Department of Pharmacy National University of Singapore, Republic of Singapore

Thailand

• Nathorn Chaiyakunapruk PharmD, PhD, Assistant Professor, Department of Pharmacy Practice,  School of Pharmacy, Naresuan University, Pitsanuloak, Thailand
• Surachat Ngorsuraches PhD, RPh,  Faculty of Pharmaceutical Sciences Prince of Songkla University  Hatyai, Songkhla Thailand
• Vithaya Kulsomboon PhD, Associate Professor, Chair of Social Pharmacy Department, and Director of Graduate Program in Social and Administrative Pharmacy Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand

Industry

• Zhiqiang Guan, MD, MPH, Director, National Institute for Social Insurance, Beijing, China
• Jittrakul Leartsakulpanitch B.Sc.(Pharmacy), Msc, PhD, Outcomes Research Associate, Pfizer (Thailand) Ltd., Bangkok, Thailand
• Alison Tan-Mulligan PhD, Health Outcome & Epidemiology Manager, GlaxoSmithKline China Investment Co. Ltd, Shanghai, China 

Asia Consortium Advisory Committee Chair

Jeff J. Guo B. Pharm., PhD, Associate Professor of Pharmacoeconomics & Pharmacoepidemiology, Division of Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy (& Faculty Research Fellow, Institute for the Study of Health), University of Cincinnati Medical Center, Cincinnati, OH, USA

Back to Asia Consortium main page